Skip to main content
Erschienen in: Clinical and Experimental Medicine 3/2013

01.08.2013 | Original Article

Significantly higher procalcitonin levels could differentiate Gram-negative sepsis from Gram-positive and fungal sepsis

verfasst von: Helena Brodská, Karin Malíčková, Václava Adámková, Hana Benáková, Markéta Marková Šťastná, Tomáš Zima

Erschienen in: Clinical and Experimental Medicine | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Procalcitonin (PCT) levels can distinguish between infectious and non-infectious systemic inflammatory response. However, there are some differences between Gram-negative (G−), Gram-positive (G+), and fungal bloodstream infections, particularly in different cytokine profiles, severity and mortality. The aim of current study was to examine whether PCT levels can serve as a distinguishing mark between G+, G−, and fungal sepsis as well. One hundred and sixty-six septic patients with positive blood cultures were examined on C-reactive protein (CRP) and PCT on the same date of blood culture evaluation. The median (interquartile range, IQR) of CRP and PCT in G+, G−, and fungal cohorts and comparison of measured values between groups were made using the Kruskal–Wallis test with subsequent Bonferroni’s corrections, with p < 0.05. In 83/166 (50 %) of blood cultures, G+ microbes, 78/166 (47 %) G− rods, and 5/166 (3 %) fungi were detected. PCT concentrations (ng/ml) were significantly higher in G− compared to other cohorts: 8.90 (1.88; 32.60) in G−, 0.73 (0.22; 3.40) in G+, and 0.58 (0.35; 0.73) in fungi (p < 0.00001). CRP concentrations did not differ significantly in groups. Significantly higher PCT levels could differentiate G− sepsis from G+ and fungemia. In contrast to CRP, PCT is a good discriminative biomarker in different bloodstream infections.
Literatur
1.
Zurück zum Zitat Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H et al (2006) Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34:344–353PubMedCrossRef Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H et al (2006) Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34:344–353PubMedCrossRef
2.
Zurück zum Zitat ACCP-SCCM Consensus Conference (1992) Definitions of sepsis and multiple organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992(20):864–874 ACCP-SCCM Consensus Conference (1992) Definitions of sepsis and multiple organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992(20):864–874
3.
Zurück zum Zitat (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis DefinitionsConference. Crit Care Med 31:4 (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis DefinitionsConference. Crit Care Med 31:4
4.
Zurück zum Zitat Pierrakos CH, Vincent JL (2010) Sepsis biomarkers: a review. Cri Care 14(1):R15CrossRef Pierrakos CH, Vincent JL (2010) Sepsis biomarkers: a review. Cri Care 14(1):R15CrossRef
5.
Zurück zum Zitat Simon L, Gauvin F, Saint Louis P, Lacroix J (2004) Serum procalcitonin and C-reactive levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39:206–217PubMedCrossRef Simon L, Gauvin F, Saint Louis P, Lacroix J (2004) Serum procalcitonin and C-reactive levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39:206–217PubMedCrossRef
6.
Zurück zum Zitat Reinhart K, Meisner M (2011) Biomarkers in the critically ill patient: procalcitonin. Crit Care Clin 27:253–263PubMedCrossRef Reinhart K, Meisner M (2011) Biomarkers in the critically ill patient: procalcitonin. Crit Care Clin 27:253–263PubMedCrossRef
7.
Zurück zum Zitat Brunkhorst FM, Wegscheider K, Forycki ZF, Brunkhorst R (2000) Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med 26:S148–S152PubMed Brunkhorst FM, Wegscheider K, Forycki ZF, Brunkhorst R (2000) Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med 26:S148–S152PubMed
8.
Zurück zum Zitat Reinhart K, Meisner M (2006) Markers for sepsis diagnosis: what is useful? Crit Care Clin 22:503–519PubMedCrossRef Reinhart K, Meisner M (2006) Markers for sepsis diagnosis: what is useful? Crit Care Clin 22:503–519PubMedCrossRef
9.
Zurück zum Zitat Gao H, Evans TW, Finney SJ (2008) Bench-to-bedside review: sepsis, severe sepsis and septic shock—does the nature of the infecting organism matter? Crit Care 12(3):213PubMedCrossRef Gao H, Evans TW, Finney SJ (2008) Bench-to-bedside review: sepsis, severe sepsis and septic shock—does the nature of the infecting organism matter? Crit Care 12(3):213PubMedCrossRef
10.
Zurück zum Zitat Feezor RJ, Oberholzer C, Baker HV, Novick D, Rubinstein M, Moldawer LL et al (2003) Molecular characterization of the acute inflammatory response to infections with gram-negative versus gram-positive bacteria. Infect immune 7:5803–5813CrossRef Feezor RJ, Oberholzer C, Baker HV, Novick D, Rubinstein M, Moldawer LL et al (2003) Molecular characterization of the acute inflammatory response to infections with gram-negative versus gram-positive bacteria. Infect immune 7:5803–5813CrossRef
11.
Zurück zum Zitat Bjere A, Brusletto B, Holby EA, Kjerulf P, Brandtzaeg P (2004) Plasma Interferon gamma and interleukin 10 concentration in systemic meningococcal disease compared with severe systemic Gram-positive septic shock. Crit Care Med 32:433–438CrossRef Bjere A, Brusletto B, Holby EA, Kjerulf P, Brandtzaeg P (2004) Plasma Interferon gamma and interleukin 10 concentration in systemic meningococcal disease compared with severe systemic Gram-positive septic shock. Crit Care Med 32:433–438CrossRef
12.
Zurück zum Zitat Mohamed MA, Cunningham-Rundles S, Dean CR, Hammad TA, Nesin M (2007) Levels of proinflammatory cytokines produced from cord blood in vitro are pathogen dependent and increased in comparison to adult controls. Cytokine 39:171–177PubMedCrossRef Mohamed MA, Cunningham-Rundles S, Dean CR, Hammad TA, Nesin M (2007) Levels of proinflammatory cytokines produced from cord blood in vitro are pathogen dependent and increased in comparison to adult controls. Cytokine 39:171–177PubMedCrossRef
13.
Zurück zum Zitat Charles PE, Ladoire S, Aho S, Quenot JP, Doise JM, Prin S (2008) Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either gram negative or gram positive bacteria. BMC Infect Dis 8:38PubMedCrossRef Charles PE, Ladoire S, Aho S, Quenot JP, Doise JM, Prin S (2008) Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either gram negative or gram positive bacteria. BMC Infect Dis 8:38PubMedCrossRef
14.
Zurück zum Zitat Abe R, Oda S, Sadahiro T, Nakamura M, Hirayama Y, Tateishi Y (2010) Gram-negative bacteremia induces greater magnitude of inflammatory response than gram-positive bacteremia. Crit Care 14:R27PubMedCrossRef Abe R, Oda S, Sadahiro T, Nakamura M, Hirayama Y, Tateishi Y (2010) Gram-negative bacteremia induces greater magnitude of inflammatory response than gram-positive bacteremia. Crit Care 14:R27PubMedCrossRef
15.
Zurück zum Zitat Martini A, Gottin L, Menestrina N, Schweiger V, Simion D, Vincent JL (2010) Procalcitonin levels in surgical patients at risk of candidemia. J Infect 60:425–430PubMedCrossRef Martini A, Gottin L, Menestrina N, Schweiger V, Simion D, Vincent JL (2010) Procalcitonin levels in surgical patients at risk of candidemia. J Infect 60:425–430PubMedCrossRef
16.
Zurück zum Zitat Montagna MT, Coretti C, Caggiano P (2011) Procalcitonin: a possible marker of invasive fungal infection in high risk patients? J Prev Hyg 52:38–39 Montagna MT, Coretti C, Caggiano P (2011) Procalcitonin: a possible marker of invasive fungal infection in high risk patients? J Prev Hyg 52:38–39
17.
Zurück zum Zitat Vincent JL, Donadello K, Schmidt X (2011) Biomarkers in the critically ill patient: C-reactive protein. Crit Care Clin 27:241–251PubMedCrossRef Vincent JL, Donadello K, Schmidt X (2011) Biomarkers in the critically ill patient: C-reactive protein. Crit Care Clin 27:241–251PubMedCrossRef
18.
Zurück zum Zitat Delevaux I, Andre M, Colombier M, Albuisson E, Meylheuc F, Bégueet RJ (2003) Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Rheum Dis 62:337–340CrossRef Delevaux I, Andre M, Colombier M, Albuisson E, Meylheuc F, Bégueet RJ (2003) Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Rheum Dis 62:337–340CrossRef
Metadaten
Titel
Significantly higher procalcitonin levels could differentiate Gram-negative sepsis from Gram-positive and fungal sepsis
verfasst von
Helena Brodská
Karin Malíčková
Václava Adámková
Hana Benáková
Markéta Marková Šťastná
Tomáš Zima
Publikationsdatum
01.08.2013
Verlag
Springer Milan
Erschienen in
Clinical and Experimental Medicine / Ausgabe 3/2013
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-012-0191-8

Weitere Artikel der Ausgabe 3/2013

Clinical and Experimental Medicine 3/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.